Journal Club September 29, Vanessa AKIKI PGYlII Internal Medicine
|
|
- Vincent Baker
- 6 years ago
- Views:
Transcription
1 Journal Club September 29, 2017 Vanessa AKIKI PGYlII Internal Medicine AUBMC 2017
2 Case Presentation 41-year-old man who was diagnosed with type 1 diabetes 21 years ago presents to your clinic. He believes that his diabetes has been fairly well controlled during the past 20 years and that his insulin needs have been the same for the last year. He would like help in losing 10 lb. His body mass index is 25 kg/m2. His medications include pravastatin (Pravacol), 10 mg daily; Amlodipine 10 mg daily, NPH insulin, 34 units in the morning and 13 units at bedtime; and regular insulin at breakfast and dinner following a sliding-scale algorithm. He also takes lispro (Humalog) insulin as needed to correct high blood glucose. He is not checking his blood glucose on a regular basis. No hypoglycemic episodes, no Recent DKA within the last years.
3 Case Presentation ROS: otherwise negative Allergies :NKDA PMH: DM type 1, DLP, HTN PSH: Negative FHx : DM type 1 brother Social: smoking-, EtOH Lab Tests: A1C: 8.3% (normal %) Creatinine: 0.9 mg/dl (normal: mg/dl) Microalbumin: 4 g (normal: 0 29 g) You tell him: Please come back with dextro charting and I would like to increase your insulin doses to achieve an Hba1c of less than 7.
4 Case Presentation Dr.,Can you add a pill that helps me control my sugar level instead of increasing my insulin dose?..as you know Dr.,I am trying to loose weight and more insulin would make this task more difficult
5 PICO Patient : Patient with DM 1 Intervention : Add sotagliflozin to insulin Comparison : Placebo + insulin Outcome : HbA1c < 7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis
6
7 InTandem3 Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin TherapyAlone (intandem3) Results were presented September 13 at the European Association for the Study of Diabetes (EASD) 2017 Annual Meeting. They were simultaneously published in the New England Journal of Medicine.
8 InTandem3 : Sotagliflozin SGLT1 and SGLT2 inhibitor
9 Patient Population Men and nonpregnant women : > 18 years of age type 1 diabetes for at least 1 year Treatment with insulin at a stable basal dose for at least 2 weeks before the screening visit HbA1c : 7.0 to 11.0% BMI > 18.5
10 Exclusion Criteria Severe hypoglycemia during the previous month Diabetic ketoacidosis during the previous month 2 or more episodes of diabetic ketoacidosis during the previous 6 months GFR <45 ml per minute per 1.73 m2 of body-surface area.
11 Design From October 2015 through September 2016 multicenter, randomized, double-blind, placebo-controlled trial Conducted at 133 sites in 19 countries patients were randomly assigned, in a 1:1 ratio, to receive either sotagliflozin (400 mg per day) or placebo for 24 weeks Modified intentionto-treat 1405 patients underwent randomization 1402 patients were included 699 patients in the sotagliflizin group 703 patients in the placebo group
12 End Points Primary outcomes HBa1c < 7.0% at week 24 with no episodes of severe hypoglycemia or diabetic ketoacidosis Secondary outcomes the change from baseline to week 24 in: glycated hemoglobin level body weight mean daily bolus dose of insulin systolic blood pressure
13 Statistical Analysis 700 patients per trial group >90% power, effect size 0.10 assuming that 50% of the participants overall would achieve the primary end point the null hypothesis of no treatment effect was tested at a two-sided alpha level of Categorical variables were analyzed as proportions Safety analyses were descriptive.
14 RCT Critical Appraisal 1- Internal Validity 2- Results 3- External Validity / Applicability
15 RCT Appraisal: Internal Validity Was the assignment of patients to treatments randomised? YES eligible patients were randomly assigned, in a 1:1 ratio, to receive either sotagliflozin (400 mg per day) or placebo for 24 weeks. Was randomization concealed? YES
16 RCT Appraisal: Internal Validity Were all patients analyzed in the groups to which they were randomized? NO 1405 patients underwent randomization,1402 patients were included in the modified intention-to-treat population Were Patients in the treatment and control groups similar with respect to known prognostic variables? YES
17
18 RCT Appraisal: Internal Validity Were the patients and clinicians kept blind to which treatment was being received? YES In the sotagliflozin group, patients received the 400-mg dose of sotagliflozin as two 200-mg oral tablets.in the placebo group, patients took two matching placebo tablets in the same manner Independent clinical end-point committee, whose members were unaware of the treatment assignments, adjudicated events of special interest Was follow up complete? YES Efficacy and safety were assessed at prespecified times during the treatment period, and a final safety assessment was performed 30 days after the last dose of the trial regimen was administered.
19 Results What are the results? How large was the treatment effect? How precise was the estimate of the treatment effect?
20 Results
21 Results outcome No outcome Total Sotagliflozin Placebo ARR = EER-CER = 200/ /703 = 13.4 NNT = 1/ARR= 7.8 RRR= EER-CER/CER = 0.88 = 88 %
22 Results
23 Results In the Sotagliflozin group : The reduction in body weight : significantly greater (difference, 2.98 kg; P<0.001). reductions from baseline in the mean daily total, bolus, and basal doses of insulin were 5.3 units per day ( 9.7%), 2.8 units per day ( 12.3%), and 2.6 units per day ( 9.9%), respectively (P<0.001 for all comparisons). reduction in systolic blood pressure from baseline was greater (difference, 3.5 mm Hg; P = 0.002) BUT
24 Results
25 Results
26 LIMITATIONS Longterm effects of sotagliflozin cannot be determined from this 24-week trial. glycated hemoglobin levels were masked to investigators after screening if investigators had had access to the data, they may have adjusted insulin therapy more aggressively to meet target. measures to mitigate the risk of diabetic ketoacidosis that may have been more intensive than those used in typical clinical practice. Data from continuous glucose monitoring were not analyzed in this trial. No artificial pancreas system had been approved at the time of trial initiation.
27 RCT Appraisal: External Validity / Applicability 3.How can I apply the results to patient care? Were the study patients similar to my patient? > 18 yo type 1 diabetes for at least 1 year Treatment with insulin at a stable basal dose for at least 2 weeks before the screening visit HbA1c : 7.0 to 11.0% BMI > 18.5
28 RCT Appraisal: External Validity / Applicability Were all clinically important outcomes considered? YES Are the likely treatment benefits worth the potential harm and costs? NO Harms : diabetic ketoacidosis severe hypoglycemia > sotagliflozin Costs:
29 RCT Appraisal: External Validity / Applicability
30 Thank You for your Attention!
Non-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationSafety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus Journal Club (May 2013) Sara Al-Sharhan, Pharm D intern-
More informationLOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA
LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA Anne Leake, PhD, APRN-Rx, BC-ADM ECHO Diabetes Learning Group 3/28/2018 Objectives 1. Identify common preventable causes of hypoglycemia
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationCritical Appraisal of Evidence
Critical Appraisal of Evidence A Focus on Intervention/Treatment Studies Bernadette Mazurek Melnyk, PhD, CPNP/PMHNP, FNAP, FAAN Associate Vice President for Health Promotion University Chief Wellness Officer
More informationOutline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:
Evidence Based Practice Primer Outline Evidence Based Practice (EBP) EBP overview and process Formulating clinical questions (PICO) Searching for EB answers Trial design Critical appraisal Assessing the
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCritical Appraisal of Evidence A Focus on Intervention/Treatment Studies
Critical Appraisal of Evidence A Focus on Intervention/Treatment Studies Bernadette Mazurek Melnyk, PhD, CPNP/PMHNP, FAANP, FAAN Associate Vice President for Health Promotion University Chief Wellness
More informationComplete this CE activity online at ProCE.com/InsulinPart2
Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over
More informationGLOSSARY OF GENERAL TERMS
GLOSSARY OF GENERAL TERMS Absolute risk reduction Absolute risk reduction (ARR) is the difference between the event rate in the control group (CER) and the event rate in the treated group (EER). ARR =
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationCASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
More informationa) Subjects must be willing and able to give signed and dated written informed consent.
Detailed inclusion and exclusion criteria Inclusion Criteria 1) Signed Written Informed Consent a) Subjects must be willing and able to give signed and dated written informed consent. 2) Target Population
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationSafe use of insulin regular concentrated (500 units/ml) in severe insulin resistance
Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System Objectives To be
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationGlycemic Control IU Health Diabetes Centers
Glycemic Control IU Health Diabetes Centers Central Nursing Orientation 3/10/2014 1 Objectives Identify laboratory results that diagnosis diabetes and reflect glycemic control Describe glycemic control
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationArabian Gulf University Kingdom of Bahrain Year 5 Internal Medicine Critical Appraisal of Medical Article (2) Critical Appraisal (Form A)
Arabian Gulf University Kingdom of Bahrain Year 5 Internal Medicine Critical Appraisal of Medical Article (2) Critical Appraisal (Form A) - What is Your Search question from the case history? How efficient
More informationEBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University
EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?
More informationGli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1?
Impatto degli inibitori di SGLT-2 nei pazienti con diabete di tipo 2 Corso SID Hotel Michelangelo, Milano. 26 Giugno 2018 Gli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1? Emanuele
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationDiabetic Ketoacidosis
October 2015 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Case History HPI: 24 yo man with recent 8 lb. weight loss, increased thirst and frequent
More informationCASE STUDY Diabetes Mellitus FH: PMH: Social Hx PE: Labs: Rx: CAM: Dx: Plan:
CASE STUDY Diabetes Mellitus Patricia C. is a 30 yo Asian American woman with T1DM. She was diagnosed at age 13. Her insulin regimen is 50 units of insulin (Glargine) every evening and 3 units of Lispro
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationSotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus
NIHR Innovation Observatory Evidence Briefing: September 2017 Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus NIHRIO (HSRIC) ID: 8655 NICE ID: 9521 LAY SUMMARY Type 1
More informationJournal Club: Fairfax Internal Medicine. Stephanie Shin PGY-2 Bianca Ummat PGY-2 July 27, 2012
Journal Club: Fairfax Internal Medicine Stephanie Shin PGY-2 Bianca Ummat PGY-2 July 27, 2012 S Objective Review EBM basic principles Learn how to apply the principles in critically appraising the article.
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationHYPERGLYCEMIA MANAGEMENT PROTOCOL A BASAL/BOLUS REGIMEN. Kacy Aderhold, MSN, APRN-CNS, CMSRN
HYPERGLYCEMIA MANAGEMENT PROTOCOL A BASAL/BOLUS REGIMEN Kacy Aderhold, MSN, APRN-CNS, CMSRN Hyperglycemia Management Protocol Mimics the body s normal pancreas function, releasing a slow steady amount
More informationCritical Appraisal Series
Definition for therapeutic study Terms Definitions Study design section Observational descriptive studies Observational analytical studies Experimental studies Pragmatic trial Cluster trial Researcher
More informationJournal Club PowerPoint Template. A Question of Therapy RCT
Journal Club PowerPoint Template A Question of Therapy RCT 1 EBM Process Ask a well built (focused) clinical question Search for the best evidence to answer the question Critically appraise the evidence
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationGLUCOSE MONITORING. How. When
GLUCOSE MONITORING Why Self-monitoring of blood glucose is the best way to see how your body handles food, activity, diabetes medication (pills and/or insulin), stress and illness. You can also see what
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationSupplemental Health Record and Authorization for Care of Child with Insulin Dependent Diabetes
477 Beaverkill Road Olivebridge, New York 12461 (845) 657-8333 Ext. 15 Fax (845) 657-8489 martin.bernstein@ashokancenter.org www.ashokancenter.org 2012-13 Supplemental Health Record and Authorization for
More informationDIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:
1 DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address: 2 Learning Outcomes All nurses, regardless of practice setting, are required to work collaboratively with the person
More informationManagement of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth
Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationCHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female
More informationUse of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations
Diabetes Ther (2017) 8:1265 1296 DOI 10.1007/s13300-017-0328-6 REVIEW Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations Gary Deed. Gary Kilov. Trisha
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationMeghan Ames Mrs. Matuszak KNH 406 March 18, 2010 Diabetes Case Study #4 Understanding the Disease and Pathophysiology 1) Define insulin. Describe its major functions within normal metabolism. Insulin is
More informationManagement of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Hyperglycemia in Critically ill patients in ICU Settings.
Management of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Guillermo E. Umpierrez, MD, Emory University School of Medicine and Jack Leahy, MD, University of Connecticut Hyperglycemia in Critically
More informationNEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes
NEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes Moderated by: Bernard Zinman, MD, CM, FRCPC, FACP Lunenfeld-Tanenbaum Research Institute and University of Toronto Mount Sinai Hospital
More informationManagement: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018
Management: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018 Disclosures I have no Objectives Use a case-based format to discuss diabetes management pearls Discuss
More informationTo assess the safety and tolerability in each treatment group.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationManagement of Gestational Diabetes
Management of Gestational Diabetes A Diabetes risk assessment should be ascertained at the First prenatal visit. Low Risk: Early blood glucose screening is NOT routinely required if most of the following
More informationThe comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.
1. RANDOMISED CONTROLLED TRIALS (Treatment studies) (Relevant JAMA User s Guides, Numbers IIA & B: references (3,4) Introduction: The most valid study design for assessing the effectiveness (both the benefits
More informationCurrent Glucometers. Junior s s Glucose Log. All have advantages and disadvantages Answer 2
Diabetes Dilemmas: Using Technology To Solve Clinical Conundrums Stephen E. Gitelman, MD UCSF A teenager with type 1 diabetes for 5 years comes into your office for a follow- up visit. You want to review
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationLearning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications
Treatment Strategies to Maximize the Value of Diabetes Medications Presenters: Jennifer Toy, PharmD, BCACP and Crystal Zhou, PharmD, APh AHSCP, BCACP Learning Objectives 1. Discuss which patients may benefit
More informationRCHC Clinical Guidelines Type 2 Diabetes; Adults
RCHC Clinical Guidelines Type 2 Diabetes; Adults Screening for diabetes in asymptomatic adults 1 Population: Aged > 45 years; Aged < 45 years who are overweight (BMI> 25kg/m 2 ) and have an additional
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationContinuous or Intermittent Glucose Monitoring in Interstitial Fluid
Continuous or Intermittent Glucose Monitoring in Interstitial Fluid Policy Number: 1.01.20 Last Review: 9/2018 Origination: 11/2001 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationInpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin
Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin David Newman, MD University of North Dakota School of Medicine Sanford Health Big Sky Conference 2017 Dr. David Newman, Personal/Professional
More informationA Guidance Statement from the American College of Physicians
Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,
More informationJanuary 7, 5:00 p.m. EST
Study 3-151 Phase 2 Trial: Preliminary Results BIOD-531, a Concentrated Ultra-Rapid-Acting Prandial/Basal Insulin, Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationInvestigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD
STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Page 1 of 39 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Continuous or Intermittent Monitoring
More informationReason for referral: provide patient education on management of hypoglycemia and glucose monitor
Meet Robin Sawyer (otherwise known as PT 1): Let s Create a Care Plan! Reason for referral: provide patient education on management of hypoglycemia and glucose monitor History of present illness: 40 45
More informationTransition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationTo test your basal rates it will be important that you keep the same schedule on the days you are testing. Do not do basal rate testing if you:
Basal Rate Testing: Your provider has recommended that you complete one or more basal rate tests. These worksheets will help you in testing your pump settings and making small changes to make sure your
More informationAdvanced Pharmacology Diabetes Homework
Advanced Pharmacology Diabetes Homework Points: 25 Comments: Name: Tracy Hill WU ID #: 20015608 E-mail: tracy.hill@washburn.edu _TH I hereby certify that the work submitted is my own, and that I have not
More informationTHERAPY WORKSHEET: page 1 of 2 adapted from Sackett 1996
THERAPY WORKSHEET: page 1 of 2 adapted from Sackett 1996 Citation: Are the results of this single preventive or therapeutic trial valid? Was the assignment of patients to treatments randomised? -and was
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationLearning Objectives. Perioperative SWEET Success
Perioperative SWEET Success PERIOPERATIVE SWEET SUCCESS PRESENTED BY: KENDRA MARTIN, RN, BSN, CDE JENNIFER SIMPSON, RN, BC-ADM, MSN, CNS Disclosure to Participants Notice of Requirements For Successful
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationManaging Problematic Hypoglycaemia Pratik Choudary
Managing Problematic Hypoglycaemia Pratik Choudary Control Hypoglycaemia What is normal? Rate per 100 years 100 80 60 40 Is tighter control associated with more severe hypoglycaemia? Intensive Conventional
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More information